Onkologie. 2022:16(5):246-249 | DOI: 10.36290/xon.2022.046

Dose escalation in the treatment of NSCLC with proton radiotherapy

Alexandra Haas
Proton Therapy Center Czech, s. r. o., Praha

Radiation therapy is an essential component of treatment for early stages and also for locally advanced non-small cell lung cancer (NSCLC), but can be technically challenging because of the proximity of lung tumors to nearby critical organs. Using proton therapy offers the potential for further advantages because of the unique depth-dose characteristics of the particles (Bragg peak), which can allow higher dose escalation to tumors with greater sparing of normal tissues, with the ultimate goal of improving local tumor control and survival while preserving quality of life by reducing treatment-related toxicity.

Keywords: NSCLC (non small cell lung cancer), dose escalation, proton radiotherapy.

Accepted: September 29, 2022; Published: September 29, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Haas A. Dose escalation in the treatment of NSCLC with proton radiotherapy. Onkologie. 2022;16(5):246-249. doi: 10.36290/xon.2022.046.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mesko S, Gomez D. Proton Therapy in Non-small Cell Lung Cancer. Curr Treat Options Oncol. 2018;19(12):76. Go to original source... Go to PubMed...
    2. Novotvary 2017. Cancer incidence2017 in Czech Republic: UZIS ČR, NOR ČR; 2017.
    3. Curran WJ, Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452-1460. Go to original source... Go to PubMed...
    4. Antonia SJ, Villegas A, Daniel D, et al. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. Go to original source... Go to PubMed...
    5. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187-199. Go to original source... Go to PubMed...
    6. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced Non-Small-Cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. JCO. 2017;35:56-62. Go to original source... Go to PubMed...
    7. Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012;82(1):425-434. Go to original source... Go to PubMed...
    8. Bush DA, Cheek G, Zaheer S, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013;86(5):964-968. Go to original source... Go to PubMed...
    9. Oshiro Y, Okumura T, Kurishima K, et al. High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study. J Radiat Res. 2014;55(5):959-965. Go to original source... Go to PubMed...
    10. Jeter MD, Gomez D, Nguyen QN, et al. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018;100(3):730-737. Go to original source... Go to PubMed...
    11. Hanley J, Debois MM, Mah D, et al. Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation. Â Int J Radiat Oncol Biol Phys. 1999;45(3):603-611. Go to original source... Go to PubMed...
    12. Chang JY, Jabbour SK, De Ruysscher D, et al. International Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016;95(1):505-516. Go to original source... Go to PubMed...
    13. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070-1076. Go to original source...
    14. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630-637. Go to original source... Go to PubMed...
    15. Gomez DR, Li H, Chang JY. Proton therapy for early-stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2018;7(2):199-204.Další literatura u autorky a na www.onkologiecs.cz Go to original source... Go to PubMed...
    16. Bush DA, Cheek G, Zaheer S, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013;86(5):964-968. Go to original source... Go to PubMed...
    17. Register SP, Zhang X, Mohan R, et al. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;80(4):1015-1022. Go to original source... Go to PubMed...
    18. Kadoya N, Obata Y, Kato T, et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;79(4):1225-1231. Go to original source... Go to PubMed...
    19. Shi W, Nichols RC Jr, Flampouri S, et al. Proton-based chemoradiation for synchronous bilateral non-small-cell lung cancers: A case report. Thorac Cancer. 2013;4(2):198-202. Go to original source... Go to PubMed...
    20. Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;80(5):1350-1357. Go to original source... Go to PubMed...
    21. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929. Go to original source... Go to PubMed...
    22. National Comprehensive Cancer Network (NCCN) Guidelines. Non-Small Cell Lung Cancer. 2019; version 5.
    23. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326(8):524-530. Go to original source... Go to PubMed...
    24. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452-1460. doi: 10.1093/jnci/djr325. Epub 2011 Sep 8. Erratum in: J Natl Cancer Inst. 2012;104(1):79. Go to original source... Go to PubMed...
    25. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011; Mar 22. Go to original source... Go to PubMed...
    26. Oshiro Y, Okumura T, Kurishima K, et al. High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study. J Radiat Res. 2014;55(5):959-965. Go to original source... Go to PubMed...
    27. Hoppe BS, Henderson R, Pham D, et al. A Phase 2 Trial of Concurrent Chemotherapy and Proton Therapy for Stage III Non-Small Cell Lung Cancer: Results and Reflections Following Early Closure of a Single-Institution Study. Int J Radiat Oncol Biol Phys. 2016;95(1):517-522. Go to original source... Go to PubMed...
    28. Sejpal S, Komaki R ,Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011;117:3004-3013. Go to original source... Go to PubMed...
    29. Wang XS, Shi Q, Williams LA, et al. Prospective study of patient-reported symptom burden in patients with non-small-cell lung cancer undergoing proton or photon chemoradiation therapy. J Pain Symptom Manage. 2016;51:832-838. Go to original source... Go to PubMed...
    30. Liao Z, Lee JJ, Komaki R, et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced Non-Small-Cell lung cancer. JCO. 2018;36:1813-1822. Go to original source... Go to PubMed...
    31. Zhang X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study. Int. J. Radiation Oncology Biol. Phys. 2010;77(2): pp. 357-366. Go to original source... Go to PubMed...
    32. Elhammali A, Blanchard P, Yoder A, et al. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol. 2019;136:136-142. Go to original source... Go to PubMed...
    33. Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys. 2001;49:973-985. Go to original source... Go to PubMed...
    34. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627-1639. Go to original source... Go to PubMed...
    35. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14:981-988. Go to original source... Go to PubMed...
    36. Shahed NB, Rutenberg MS, et al. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies, Original report. Practical radiation Oncology. 2019;(9):4 p.280-288. Go to original source... Go to PubMed...
    37. Simone CB, Rengan R. The use of proton therapy in the treatment of lung cancers. Cancer. 2014;20:427-432. Go to original source... Go to PubMed...
    38. McAvoy SA, Ciura KT, Rineer JM, et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013;109:38-44. Go to original source... Go to PubMed...
    39. Rutenberg MS, Nichols RC, Flampouri S, et al. Proton radiotherapy in reirradiation for recurrent nsclc. Int J Particle Ther. 2014;1:774-775.
    40. Ho JC, Nguyen QN, Li H, et al. Reirradiation of thoracic cancers with intensity modulated proton therapy. Pract Radiat Oncol. 2018;8:58-65. Go to original source... Go to PubMed...
    41. Chao HH, Berman AT, Simone CB, 2nd, et al. Multi-institutional prospective study of reirradiation with proton beam radiotherapy for locoregionally recurrent non-small cell lung cancer. J Thorac Oncol. 2017;12:281-292. Go to original source... Go to PubMed...
    42. McAvoy S, Ciura K, Wei C, et al. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014;90:819-827. Go to original source... Go to PubMed...
    43. McAvoy SA, Ciura KT, Rineer JM, et al. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013;109:38-44. Go to original source... Go to PubMed...
    44. Chao HH, Berman AT, Simone CB 2nd, et al. Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12:281-292. Go to original source... Go to PubMed...
    45. Vyfhuis MAL, Rice S, Remick J, et al. Reirradiation for locoregionally recurrent non-small cell lung cancer: Review Article J Thorac Dis. 2018;10(Suppl 21): S2522-S2536. Go to original source... Go to PubMed...
    46. Homolka J, Altmann V, Votava V. Increasing prevalence of idiopathic pulmonary fibrosis in the Czech Republic. Chest. 1999;116 (Suppl 2):155.
    47. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161(1):5-8. Go to original source... Go to PubMed...
    48. Koizumi K, Hirata T, Hirai K, et al. Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. Ann Thorac Cardiovasc Surg. 2004;10(6):340-6.
    49. Kanzaki M, Kikkawa T, Maeda H, et al. Acute exacerbation of idiopathic interstitial pneumonias after surgical resection of lung cancer. Interact Cardiovasc Thorac Surg. 2011;13(1):16-20. Go to original source... Go to PubMed...
    50. Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147(5):1604-1611. Go to original source... Go to PubMed...
    51. Yamaguchi S, Ohguri T, Ide S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82(2):260-265. Go to original source... Go to PubMed...
    52. Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience. Radiat Oncol. 2016; (11):56. https://doi.org/10.1186/s13014-016-0637-3. Go to original source... Go to PubMed...
    53. Kim H, Pyo H, Noh JM, et al. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol. 2019;(14):19. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.